AK112 + Nab-paclitaxel + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-Negative Breast Cancer (TNBC)
Conditions
Triple-Negative Breast Cancer (TNBC)
Trial Timeline
Feb 7, 2025 → Dec 1, 2028
NCT ID
NCT06767527About AK112 + Nab-paclitaxel + Placebo
AK112 + Nab-paclitaxel + Placebo is a phase 3 stage product being developed by Akeso for Triple-Negative Breast Cancer (TNBC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06767527. Target conditions include Triple-Negative Breast Cancer (TNBC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06767527 | Phase 3 | Recruiting |
Competing Products
20 competing products in Triple-Negative Breast Cancer (TNBC)